Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

OBJECTIVE: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity. Tocilizumab, an interleukin-6 receptor antagonist, is used to treat chimeric antigen receptor T cell-induced cytokine release syndrome and may...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Edmund, Isonaka, Sharon, Yang, Haoshu, Salce, Erin, Rosales, Elisa, Jordan, Stanley C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889004/
https://www.ncbi.nlm.nih.gov/pubmed/33609773
http://dx.doi.org/10.1016/j.ijid.2021.02.057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889004/
https://www.ncbi.nlm.nih.gov/pubmed/33609773
http://dx.doi.org/10.1016/j.ijid.2021.02.057

Ejemplares similares